Oric Pharmaceuticals
Michael Cheung has extensive experience in IT and operations, currently serving at ORIC Pharmaceuticals Inc. since May 2022. Prior roles include Senior Director of IT at Myovant Sciences from September 2018 to May 2022 and Senior Director of Informatics and Data Center at Acerta Pharma B.V. from October 2014 to August 2018. Michael has also held positions such as IT Consultant at Discovery Digital Networks, Associate Director of Infrastructure at Pharmacyclics, PM of Informatics at Genentech, and Director of IT and Information Management at Adamas Pharmaceuticals. Earlier in Michael’s career, roles included Director of Technology Operations at Gentiae Clinical Research and Manager of Information Technology at the Ischemia Research and Education Foundation. Michael earned a Bachelor of Science degree in Computer Science from the University of San Francisco between 1990 and 1994.
Oric Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering innovative treatments and targets in cancer. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.